COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.
Bertolino
Alessandro
A
Caforio
Grazia
G
Blasi
Giuseppe
G
Rampino
Antonio
A
Nardini
Marcello
M
Weinberger
Daniel R
DR
Dallapiccola
Bruno
B
Sinibaldi
Lorenzo
L
Douzgou
Sophia
S
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008715:Methionine / Q000235:genetics; D000077152:Olanzapine; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data*; D012559:Schizophrenia / Q000175:diagnosis / Q000235:genetics*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D014633:Valine / Q000235:genetics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D008715:Methionine; D002394:Catechol O-Methyltransferase; D014633:Valine; D000077152:Olanzapine